Spectral Medical Provides July Tigris Trial Update

125 patients enrolled Record July patient enrollment to start the second half of 2024 TORONTO, Canada – August 1, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and...
Read More

Spectral Medical Inc. Announces Change to Auditor

TORONTO, Canada – July 11, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that MNP LLP (“MNP”) have today been appointed as the...
Read More

Spectral Medical Provides June Tigris Trial Update

116 patients enrolled June represents a new record breaking month for patient enrollment TORONTO, Canada – July 2, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis...
Read More
Click to Hide Advanced Floating Content
EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.